Sanofi SA
Sanofi SA를 보는 글로벌 시선
이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minSector Update: Healthcare Stocks Rise in Afternoon Trading
Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St
원문 보기 ↗ YahooPress Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and Cheplapharm to create new strategic partnership in mature medicines Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their…
원문 보기 ↗ YahooINmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board
Appointments strengthen rare-disease commercialization planning and strategic partnering capabilities as Ebstrocel™ advances toward potential commercialization BOCA RATON, Fla., Sept. 14, 2026 (GLOBE …
원문 보기 ↗ YahooSanofi To Create Strategic Partnership With Cheplapharm; Cheplapharm Would Take Over From Sanofi A Selection Of 20 Mature Medicines And Three Manufacturing Sites Worldwide. In Return, Sanofi Will Receive A 26.4% Equity Stake In Cheplapharm
https://www.sanofi.com/en/media-room/press-releases/2026/2026-09-14-13-03-56-3361178
원문 보기 ↗ Benzinga5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (September 2026)
This article is part of our monthly series where we highlight 5 large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. Read it here.
원문 보기 ↗ SeekingAlphaRegeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo invest…
원문 보기 ↗ YahooSanofi: Information concerning the total number of voting rights and shares - August 2026
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement g…
원문 보기 ↗ YahooCould Remibrutinib Become the Next $9 Billion Drug for Novartis?
Novartis AG (NYSE:NVS) has reported the first major success from three closely watched pipeline programs expected to produce clinical data in 2026. Its oral drug remibrutinib outperformed Sanofi’s old…
원문 보기 ↗ YahooNovavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot
Novavax (NASDAQ:NVAX) executives outlined the company’s transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-te…
원문 보기 ↗ YahooAbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next
ABBV's Skyrizi and Rinvoq drives immunology growth, while new indications, acquisitions and partnerships build its next wave.
원문 보기 ↗ YahooGSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff
GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
원문 보기 ↗ YahooHere's Why You Should Add NRIX Stock to Your Portfolio Now
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.